Compare Norfolk Southern Corporation (NSC) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norfolk Southern Corporation vs Novartis AG — how do they compare? Norfolk Southern Corporation trades at $333 (market cap $75.23B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.9× Norfolk Southern Corporation's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NSC | NVS | |
|---|---|---|
Market Cap | $75.23B | $290.25B |
Sector | Technology | Health |
52-Week High | $340.16 | $168.62 |
52-Week Low | $272.35 | $113.50 |
Enterprise Value | $90.99B | $330.27B |
Dividend Yield | 1.61% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norfolk Southern (NSC) trades at $334.97, down 1.53% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 21.91% net income margin and has beaten earnings estimates for three consecutive quarters. Key developments include the pending Q2 2026 earnings report on July 23, 2026, and ongoing regulatory review of the proposed merger with Union Pacific, which dominates recent news coverage.
The investment outlook is cautiously optimistic, supported by earnings momentum and a consensus price target of $344.40 offering modest upside. Risks include potential regulatory hurdles for the merger, declining revenue projections for 2026, and elevated valuation multiples. The stock's current price near resistance levels suggests near-term volatility around earnings could present entry opportunities for long-term investors.
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norfolk Southern Corporation
Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
